Medical Therapy of Uveitic Macular Edema: Biologic Agents

Aleksandra Radosavljevic, Mamta Agarwal, Bahram Bodaghi, Justine R. Smith, Manfred Zierhut

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Introduction: Uveitic macular edema (UME) is a significant cause of visual impairment in all uveitis types. Methods: Reports that were cited in the MEDLINE database, that analyzed the effectiveness of biologics for UME in at least five patients, with a minimum follow-up of 3 months, published prior to April 1, 2019 were included. Reports that did not compare UME findings before and after the therapy, using either OCT or fluorescein angiography, were excluded. Results: Case series that analyzed the efficacy of intravitreal anti-VEGF agents showed modest, short-term benefit. Studies that investigated systemic anti-TNF agents in patients with noninfectious uveitis reported a therapeutic effect on UME. Anti-IL-6 antibodies have shown promising results for most severe cases of noninfectious UME. Interferon represents an option for patients with persistent UME in infectious and noninfectious uveitis. Conclusion: Multicenter, randomized controlled trials are needed to assess the effectiveness of each group of biologic agents in sufficient number of patients.

Original languageEnglish
Pages (from-to)1239-1250
Number of pages12
JournalOcular Immunology and Inflammation
Issue number8
Early online date14 Feb 2020
Publication statusPublished - 2020


  • biologic agents
  • interferon
  • interleukin 6 inhibitor
  • macular edema
  • medical therapy
  • tumor necrosis factor inhibitors
  • Uveitis
  • vascular endothelial growth factor


Dive into the research topics of 'Medical Therapy of Uveitic Macular Edema: Biologic Agents'. Together they form a unique fingerprint.

Cite this